We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
Cap. Flow
+$12.6M
Cap. Flow %
7.11%
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals
ELOX
+$5.07M
2
EDSA icon
Edesa Biotech
EDSA
+$3.85M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$3.63M
4
CABA icon
Cabaletta Bio
CABA
+$2.85M
5
MSLE
Satellos Bioscience
MSLE
+$2.69M

Top Sells

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$4.03M
2
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.46M
3
XOMA
Xoma
XOMA
+$2.18M
4
ABEO icon
Abeona Therapeutics
ABEO
+$1.04M
5
IKT icon
Inhibikase Therapeutics
IKT
+$1M

Sector Composition

Rank Sector Weight
1 Healthcare 74.11%
2 Miscellaneous 25.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IKT icon
51
Inhibikase Therapeutics
IKT
$346M
$804K 0.45%
396,179
-561,023
-59% -$1M
ZNTL icon
52
Zentalis Pharmaceuticals
ZNTL
$380M
$784K 0.44%
161,583
-107,517
-40% -$429K
CTMX icon
53
CytomX Therapeutics
CTMX
$789M
$769K 0.43%
205,000
+5,000
+3% +$19.1K
MNKD icon
54
CALL
MannKind Corp
MNKD
$1.31B
$750K 0.42%
250,000
-250,000
-50% -$812K
NVCT icon
55
Nuvectis Pharma
NVCT
$796M
$736K 0.42%
+40,000
New +$448K
CBIO
56
Crescent Biopharma
CBIO
$772M
$720K 0.41%
40,000
-45,000
-53% -$879K
PMVP icon
57
PMV Pharmaceuticals
PMVP
$69M
$718K 0.41%
536,086
-172,016
-24% -$221K
ORKA
58
Oruka Therapeutics
ORKA
$6.17B
$714K 0.4%
+7,500
New +$500K
RADX
59
Radiopharm Theranostics
RADX
$30.1M
$671K 0.38%
51,000,000
– –
OKUR
60
OnKure Therapeutics
OKUR
$144M
$596K 0.34%
130,684
-1,894
-1% -$8.13K
NGEN
61
NervGen Pharma
NGEN
$256M
$560K 0.32%
+271,678
New +$843K
CALC icon
62
CalciMedica
CALC
$15M
$545K 0.31%
+124,486
New +$441K
ARVN icon
63
Arvinas
ARVN
$612M
$499K 0.28%
60,000
+32,500
+118% +$303K
BIOA
64
BioAge Labs
BIOA
$442M
$490K 0.28%
20,000
-30,000
-60% -$542K
IRD
65
Opus Genetics
IRD
$392M
$414K 0.23%
100,718
+32,030
+47% +$149K
QTI
66
QT Imaging Holdings
QTI
$39.4M
$407K 0.23%
+100,000
New +$556K
BOLD
67
Boundless Bio
BOLD
$65.1M
$386K 0.22%
154,595
-443,087
-74% -$682K
SINT icon
68
SiNtx Technologies
SINT
$10.7M
$333K 0.19%
+209,205
New +$485K
CLRB icon
69
Cellectar Biosciences
CLRB
$22.3M
$291K 0.16%
+104,550
New +$292K
EPRX
70
Eupraxia Pharmaceuticals
EPRX
$537M
$287K 0.16%
+43,491
New +$300K
SABS icon
71
SAB Biotherapeutics
SABS
$338M
$286K 0.16%
73,271
+23,271
+47% +$86.6K
ANL
72
Adlai Nortye Group ADS
ANL
$1.01B
$279K 0.16%
+24,257
New +$295K
SENS icon
73
Senseonics Holdings Inc
SENS
$516M
$277K 0.16%
+48,680
New +$312K
PLRX icon
74
Pliant Therapeutics
PLRX
$71.2M
$263K 0.15%
230,538
+5,888
+3% +$7.17K
CDXS icon
75
Codexis
CDXS
$159M
$248K 0.14%
109,662
-308,332
-74% -$768K
1 2
3
4 5

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.

  • Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
  • Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
  • Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
  • Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
  • Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
  • Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.